Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

K3502

Sigma-Aldrich

Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat

affinity isolated antibody, lyophilized powder

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.46

biological source

goat

Quality Level

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

form

lyophilized powder

technique(s)

quantitative precipitin assay: suitable

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... IGK@(50802)

Looking for similar products? Visit Product Comparison Guide

General description

Anti-Human κ Light Chain (bound and free) antibody is obtained from goat antiserum. Immunospecific purification removes all goat serum proteins and immunoglobulins that do not bind to the κ light chain (bound and free). The antibody preparation is specific for κ light chains when tested against bound and free light chains. The product shows no reaction with bound or free λ light chains.

Immunogen

Purified human normal and myeloma κ light chain

Application

Anti-Human κ Light Chain (Bound and Free)-FITC antibody was used for as secondary antibody in ELISA at a working antibody dilution of 1:200 using maize seed extracts. For ELISA using NSO/1 myeloma cells, HEK293 cells and mouse plasma, antibody concentration of 1-2 μg/ml was used. The antibody was also used to coat the electrode surface in the preparation of antiatrazine immunosensor.
Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat has been used in western blotting.

Physical form

Lyophilized from 0.01 M sodium phosphate, 0.015 M sodium chloride, pH 7.2

Reconstitution

Reconstitute with 0.135 M sodium chloride.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yvonne J Rosenberg et al.
PloS one, 11(3), e0152760-e0152760 (2016-04-01)
Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived
Eva Gschmack et al.
Journal of neural transmission (Vienna, Austria : 1996), 129(5-6), 545-555 (2022-04-03)
Idiopathic Parkinson's disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus-subcoeruleus complex; (stage 2)
Characterization of immunological interactions at an immunoelectrode by scanning electron microscopy
Ambrosi A et al
Electroanalysis, 19, 244-252 (2007)
Koreen Ramessar et al.
Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3727-3732 (2008-03-05)
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite
Sven Mathias et al.
Biotechnology and bioengineering, 117(1), 5-16 (2019-10-22)
Although most therapeutic monoclonal antibodies (mAbs) can routinely be produced in the multigram per litre range, some mAb candidates turn out to be difficult-to-express (DTE). In addition, the class of more complex biological formats is permanently increasing and mammalian expression

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service